Hormonoterapia raka piersi

Maciej Krzakowski

Streszczenie
Nowadays hormonal therapy should be a treatment of choice in patients with positive level of receptor before or after menopause (apart from stage of progression- it means in adjuvant as well as in palliative management). Still the golden standard of breast cancer hormonal therapy is tamoxifen, but according to post-menopausal women aromatase inhibitors are still a competition. The optimal sequence of hormonal drugs within a framework of so-called „therapeutic cascade” or using them simultaneously are still the object of studies (recent data show that using of hormonal drugs simultaneously is not any better than sequential administration-it concerns adjuvant as well as palliative hormonotherapy). The object of studies are new hormonal drugs: for example so-called „pure” antiestrogenic steroids, drugs from the SERM group (like raloxifen), drugs giving indirect effect between antiestrogens and SERM. The knowledge of existence of different receptors with partially antagonistic activity may contribute to discover selective modulators of estrogen influence on breast carcinoma cells.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.